Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Insight, 2025

DelveInsight’s, “Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cognitive Impairment Associated With Schizophrenia (CIAS): Understanding

Cognitive Impairment Associated With Schizophrenia (CIAS): Overview

Cognitive impairment associated with schizophrenia (CIAS) is a core feature of schizophrenia spectrum disorders (SSD), significantly affecting both neurocognitive and social cognition domains. It is commonly observed in the majority of individuals with SSD, often emerging before the onset of psychotic symptoms, and is a key determinant of real-world functional impairment, impacting quality of life, life engagement, and psychiatric rehabilitation outcomes. Despite its prevalence and clinical significance, CIAS remains under-addressed in routine clinical practice, even in high-income settings, due to challenges in treatment. Currently, no pharmacological agent is specifically approved for CIAS, and many antipsychotic medications can exacerbate cognitive deficits. The neurobiological mechanisms underlying CIAS are complex, involving factors like altered neural network organization, neurotransmitter imbalances, and structural brain changes. Although cognitive remediation therapies have shown some effectiveness, they face limitations in implementation. Addressing the treatment gap for CIAS is crucial, as it represents a significant barrier to recovery for people with SSD, and future research must focus on developing targeted therapies and improving clinical management strategies.

CIAS refers to a range of cognitive deficits, including impairments in attention, working memory, verbal learning, and problem-solving, that significantly impact the daily functioning of individuals with schizophrenia. These deficits often persist even when positive symptoms are managed with antipsychotic medications and are more disruptive to everyday life than traditional positive or negative symptoms. CIAS is also trait-like, present in individuals at high risk for psychosis and in non-affected first-degree relatives. Addressing CIAS is crucial, as it represents a major contributor to disability in schizophrenia, highlighting the need for targeted interventions to improve cognitive functioning and quality of life.

The pathophysiology of CIAS involves a complex interaction of neurochemical, structural, and genetic factors. Dysregulations in neurotransmitter systems, particularly glutamatergic and dopaminergic pathways, are central to the cognitive deficits seen in schizophrenia, with abnormalities in glutamate signaling and GABAergic activity contributing to local circuit dysfunction. Structural brain changes, including reduced gray matter volume in areas like the prefrontal cortex and hippocampus, are also linked to CIAS. Genetic studies suggest a hereditary component, with risk genes associated with synaptic function and neurodevelopment. These mechanisms underscore the need for targeted therapies to address cognitive impairments in schizophrenia.

The management of Cognitive Impairment Associated with Schizophrenia (CIAS) involves a combination of pharmacological and psychosocial interventions. While antipsychotic medications primarily address the positive symptoms of schizophrenia, they may also have a secondary benefit of improving cognitive function. Cognitive remediation therapy (CRT), which focuses on structured exercises to enhance cognitive skills, is a key non-pharmacological treatment. Psychosocial interventions like supportive therapy and vocational rehabilitation are also important for improving daily functioning and quality of life. Additionally, lifestyle modifications, such as regular physical exercise and a healthy diet, can support overall cognitive health in individuals with CIAS.

""Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape is provided which includes the disease overview and Cognitive Impairment Associated With Schizophrenia (CIAS) treatment guidelines. The assessment part of the report embraces, in depth Cognitive Impairment Associated With Schizophrenia (CIAS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cognitive Impairment Associated With Schizophrenia (CIAS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cognitive Impairment Associated With Schizophrenia (CIAS) R&D. The therapies under development are focused on novel approaches to treat/improve Cognitive Impairment Associated With Schizophrenia (CIAS).

Cognitive Impairment Associated With Schizophrenia (CIAS) Emerging Drugs Chapters

This segment of the Cognitive Impairment Associated With Schizophrenia (CIAS) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cognitive Impairment Associated With Schizophrenia (CIAS) Emerging Drugs

• Iclepertin: Boehringer Ingelheim International GmbH

Iclepertin is an investigational asset and a GlyT1 inhibitor that targets the brain biology linked with the cognitive symptoms associated with schizophrenia (CIAS). Iclepertin may also provide benefits for cognitive impairment in other mental health conditions. By inhibiting GlyT1, iclepertin is designed to enhance synaptic glycine levels, thereby improving NMDA receptor function and glutamatergic signaling. This mechanism holds promise for ameliorating the cognitive impairments that profoundly impact the daily lives of individuals with schizophrenia, potentially leading to improved functional outcomes and quality of life. Iclepertin has also been granted the Breakthrough Therapy Designation by the FDA for the treatment of CIAS. Currently, the drug is in Phase III stage of its development for the treatment of Cognitive Impairment Associated With Schizophrenia (CIAS).

• RL-007: Recognify Life Sciences

RL-007 (a GABA / nicotinic modulator) is a proprietary, orally available small molecule that modulates the excitatory / inhibitory balance in the brain to improve learning and memory which has been thought shown to have pro-cognitive effects. In preclinical models, RL-007 has demonstrated pro-cognitive effects in healthy young animals, age-associated memory loss, and models of cholinergic-deficits. RL-007 also showed anxiolytic properties in animal models of unconditioned anxiety. It has been shown to enhance long term potentiation in rat hippocampal slices, indicating a direct action on mechanisms and brain regions involved with learning and memory processes. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cognitive Impairment Associated With Schizophrenia (CIAS).

Further product details are provided in the report……..

Cognitive Impairment Associated With Schizophrenia (CIAS): Therapeutic Assessment

This segment of the report provides insights about the different Cognitive Impairment Associated With Schizophrenia (CIAS) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cognitive Impairment Associated With Schizophrenia (CIAS)
• There are approx. 3+ key companies which are developing the therapies for Cognitive Impairment Associated With Schizophrenia (CIAS). The companies which have their Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates in the most advanced stage, i.e. Phase II include, Boehringer Ingelheim International GmbH.
• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cognitive Impairment Associated With Schizophrenia (CIAS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cognitive Impairment Associated With Schizophrenia (CIAS) drugs.

Cognitive Impairment Associated With Schizophrenia (CIAS) Report Insights

• Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cognitive Impairment Associated With Schizophrenia (CIAS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cognitive Impairment Associated With Schizophrenia (CIAS) drugs?
• How many Cognitive Impairment Associated With Schizophrenia (CIAS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cognitive Impairment Associated With Schizophrenia (CIAS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim International GmbH
• Recognify Life Sciences
• Alto Neuroscience Inc.

Key Products

• Iclepertin
• RL-007
• ALTO-101